Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma

The objective response rate of the combination-therapy group (80.0%) was higher than that of the atezo/bev alone group (21.1%; p = 0.005). Progression-free survival (PFS) and overall survival (OS) were longer in the combination group (medians for PFS and OS not reached) than in the atezo/bev alone group (median PFS, 7.4 months; median OS, 19.8 months) (PFS, p = 0.004; OS, p < 0.001). The albumin-bilirubin score did not change, and no severe complications occurred after locoregional treatment. When performed in a minimally invasive manner, on-demand selective locoregional treatment combined with first-line atezo/bev could be safe and feasible for unresectable HCC.PMID:38534950 | PMC:PMC10969074 | DOI:10.3390/curroncol31030117

Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Tasuku Nakabori Sena Higashi Yutaro Abe Kaori Mukai Toshiki Ikawa Koji Konishi Noboru Maeda Katsuyuki Nakanishi Shinichiro Hasegawa Hiroshi Wada Kazuyoshi Ohkawa Source Type: research